
- /
- Supported exchanges
- / US
- / OCGN.NASDAQ
Ocugen Inc (OCGN NASDAQ) stock market data APIs
Ocugen Inc Financial Data Overview
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Ocugen Inc data using free add-ons & libraries
Get Ocugen Inc Fundamental Data
Ocugen Inc Fundamental data includes:
- Net Revenue: 4 522 K
- EBITDA: -54 344 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ocugen Inc News

Ocugen receives additional 180-day extension from Nasdaq to meet $1 minimum bid
Ocugen, Inc. (NASDAQ:OCGN), a $269.25 million market cap biotechnology company currently trading at $0.93, announced Tuesday it has received an additional 180 calendar days from the Nasdaq Stock Marke...


Carisma Therapeutics, OrthoCellix enter definitive merger agreement
Carisma Therapeutics (CARM) and OrthoCellix, a wholly-owned subsidiary of Ocugen (OCGN), announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tr...

Ocugen stock steady as H.C. Wainwright reiterates buy rating
Investing.com - H.C. Wainwright reiterated its buy rating and $7.00 price target on Ocugen, Inc. (NASDAQ:OCGN) on Monday, following the company’s announcement about its regenerative medicine asset. ...

Carisma and OrthoCellix to merge for knee cartilage repair therapy
PHILADELPHIA/MALVERN - Carisma Therapeutics Inc. (NASDAQ:CARM), currently trading at $0.44 with a market capitalization of $18.4 million and rated ’FAIR’ by InvestingPro’s Financial Health Score...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.